Trial Profile
Phase II trial of ARGX-110 in patients with refractory Waldenstrom's macroglobulinemia
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2015
Price :
$35
*
At a glance
- Drugs Cusatuzumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 20 Apr 2015 New trial record